Imlunestrant Overcomes ESR1 Mutant Resistance in ER-Positive Breast Cancer

Sherman S, Sandusky ZM, Russo D, et al

Here, the authors investigated the preclinical efficacy of imlunestrant in ER-positive breast cancer preclinical models, including models harboring the Y537S ESR1 mutation, an activating mutation. The results highlight the on-target and selective activity of imlunestrant, which can circumvent resistance engendered by the Y537S ESR1 mutation.